ALMDT.PA stock down 1.2% ahead of April 23 earnings at €4.89

Median Technologies SA (ALMDT.PA) trades at €4.89 on EURONEXT, down 1.2% in today’s intraday session. The French medical imaging software company faces a critical earnings announcement on April 23, 2026. With a market cap of €183.6 million and volume of 258,252 shares, ALMDT.PA stock shows mixed momentum as investors await quarterly results. The company develops AI-powered imaging platforms for clinical trials and medical device workflows. Meyka AI’s analysis reveals a complex picture for this healthcare technology player.

ALMDT.PA Stock Price Action and Technical Setup

ALMDT.PA stock opened at €4.905 and has traded between €4.66 and €5.10 today. The 52-week range spans from €1.192 to €7.27, showing significant volatility. Current price sits 33% below the yearly high, signaling weakness over the past months. The 50-day moving average stands at €4.88, nearly aligned with today’s price, suggesting consolidation. Volume of 258,252 shares represents just 59% of the average daily volume of 436,758, indicating lighter trading ahead of earnings. Technical indicators show mixed signals with RSI at 57.21, suggesting neutral momentum without clear overbought or oversold conditions.

Meyka AI Grade and Financial Health Assessment

Meyka AI rates ALMDT.PA stock with a grade of B, suggesting a Hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s financial position reveals challenges: negative earnings per share of -€1.16 and a negative PE ratio of -4.21 reflect ongoing losses. The price-to-sales ratio of 7.88 appears elevated for a loss-making company. Current ratio of 0.35 signals liquidity concerns, as current liabilities exceed current assets significantly. Working capital stands at -€27.1 million, indicating operational strain. These grades are not guaranteed and we are not financial advisors.

Revenue Growth and Profitability Trends

ALMDT.PA stock faces profitability headwinds despite modest revenue growth. Full-year 2024 revenue grew 3.2%, but gross profit declined 7.3%, showing margin compression. Net income fell 9.8% year-over-year, with earnings per share dropping 9.6%. Operating cash flow improved 11.3%, yet free cash flow remains negative at -€0.77 per share. The company burns cash operationally, raising sustainability questions. Over five years, revenue per share grew just 0.68%, indicating stagnant top-line expansion. Three-year net income growth turned negative at -9.3%, reflecting deteriorating profitability. Track ALMDT.PA on Meyka for real-time updates on cash flow trends.

Market Sentiment and Trading Activity

Trading Activity: ALMDT.PA stock shows relative weakness with volume at 59% of average, suggesting cautious positioning before earnings. The intraday decline of 1.2% reflects profit-taking after recent gains. Five-day performance gained 9.8%, indicating short-term strength that may be reversing. Year-to-date performance shows modest gains of 3.1%, while one-year returns reached 97.8%, demonstrating significant recovery from lows. Liquidation: The negative free cash flow of -€0.77 per share and debt-to-equity ratio of -0.96 suggest potential liquidity pressures. Current ratio of 0.35 indicates the company may face challenges meeting short-term obligations without asset sales or financing.

Earnings Announcement Impact and Price Forecasts

Median Technologies reports earnings on April 23, 2026 at 15:30 UTC, just two days away. This catalyst could drive significant volatility in ALMDT.PA stock. Meyka AI’s forecast model projects the following price targets: monthly forecast €4.77, quarterly forecast €5.03, and yearly forecast €3.55. The yearly forecast implies 27% downside from current levels, suggesting caution. Three-year projection of €2.58 indicates further deterioration if current trends persist. Five-year forecast of €1.57 reflects deep skepticism about long-term recovery. Forecasts are model-based projections and not guarantees. Investors should await earnings details before making decisions on ALMDT.PA stock positions.

Healthcare Sector Context and Competitive Position

ALMDT.PA stock operates in the Healthcare sector, which trades at an average PE of 29.49 on EURONEXT. Median Technologies’ negative PE reflects its unprofitable status relative to sector peers. The Medical Devices industry includes profitable competitors like EssilorLuxottica and UCB SA, which generate positive earnings. Healthcare sector performance shows -1.07% decline today, with year-to-date gains of -2.81%, indicating sector headwinds. The company’s AI-powered imaging platform (iBiops) and clinical trial services (iSee) position it in growth markets, yet execution remains challenged. With 2,250 full-time employees and research collaboration with UC, Median Technologies has infrastructure for innovation but must demonstrate profitability to justify valuations.

Final Thoughts

ALMDT.PA stock trades at a critical juncture with earnings just two days away. The €4.89 price reflects investor uncertainty about Median Technologies’ path to profitability. While revenue growth of 3.2% shows market traction, deteriorating margins and negative free cash flow raise sustainability concerns. Meyka AI’s B grade with Hold recommendation suggests waiting for clarity before committing capital. The company’s AI-powered medical imaging solutions address real market needs, yet financial metrics remain weak. Year-to-date gains of 3.1% mask underlying challenges in cash generation and profitability. Investors should monitor the April 23 earnings report closely for guidance on cost management and cash burn reduction. The forecast models suggest downside risk, making ALMDT.PA stock suitable only for risk-tolerant investors with conviction in the company’s turnaround story.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.